The Roadmap: The HIV Drug Pipeline and its Patents
Source:I-MAK 11th April,2013 The implications of last week’s Indian Supreme Court decision upholding the efficacy standard for drug patents are unmistakable. Simply put, the decision can and should...
View Article‘Novartis case: Supreme Court ruling wise and balanced’
Source: Rediff April 10,2013 The Supreme Court recently rejected the plea of Novartis [ Get Quote ] AG for patent protection of its anti-cancer drug Glivec. The Supreme Court judgement (pages 22 -26)...
View ArticleWhy are our medicines so expensive?
Source:euobserver BY ELS TORREELE BRUSSELS - In the lead-up to an inter ministerial meeting between EU and India next week, European trade negotiators continue to pressure India and other developing...
View ArticleThe Larger Implications of the Novartis-Glivec Judgment
Source: Economic and Political Weekly Vol XLVIII No.17 by Sudip Chaudhari April 27,2013 The Supreme Court judgment on the Novartis-Glivec case is remarkable because it has gone beyond the specific...
View ArticleSouth Africa seeks to close drug patent loophole
Source: Healthnexercise April 23, 2013 By Wendell Roelf CAPE TOWN (Reuters) – South Africa plans to overhaul its intellectual property laws to improve access to cheaper medicines by making it harder...
View ArticleDoctors Denounce Cancer Drug Prices of $100,000 a Year
Source: New York Times April 25,2013 With the cost of some lifesaving cancer drugs exceeding $100,000 a year, more than 100 influential cancer specialists from around the world have taken the unusual...
View Article5 Take-Home Points From India’s Historic Novartis Patent Case
Source: Asian Scientist Apr. 29, 2013– On April 1, 2013, the Indian Supreme Court dismissed the attempt by Novartis, a Swiss pharmaceutical company, to obtain patent protection for a new version of...
View ArticleThe real cancer killer: rip-off prices for drugs set by ‘profiteering’ Big...
Source: The Independent April 29,2013 An influential group of cancer experts has warned that the high prices charged by pharmaceutical companies for cancer drugs are effectively condemning patients to...
View ArticleWTO unimpressed with patent violation charges against India
Source: Hindu Business Line 26th April No country has objected to India issuing compulsory licence or refusing patent for drugs: WTO chief Pascal Lamy GENEVA: Global pharma majors are unlikely to get...
View ArticleA victory for global public health in the Indian, Ellen T Hoen
Source: Journal of Public Health Policy Abstract On 1 April of this year, the Indian Supreme Court upheld the decision of the Indian Patent Office to refuse the patent grant for Novartis imatinib...
View Article